AngioLab, Inc.

As of December 31, 2025, AngioLab, Inc. carries a market capitalization of 8.59B, placing it among publicly traded companies globally. Its enterprise value stands at 7.62B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of December 31, 2025, AngioLab, Inc. has 3.49M shares outstanding.

These figures are as of December 31, 2025. The price-to-sales ratio is 3.47, and the price-to-book ratio stands at 6.66.

These figures are as of December 31, 2025. The EV/Sales ratio of 3.36 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 7.62B versus a market cap of 8.59B, with the gap driven by net debt and cash on the balance sheet.

As of December 31, 2025, AngioLab, Inc. maintains a current ratio of 2.18, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.30, indicating moderate leverage, while an interest coverage ratio of -314.34 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2025, AngioLab, Inc. posted a negative return on equity (ROE) of -57.09, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -22.27, reflecting losses generated across the asset base. The company generates approximately 150.97M in revenue per employee across its workforce of 15.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.73 indicates how many times AngioLab, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2025, AngioLab, Inc. recorded an income tax benefit of -2.45M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -556.87M and -554.43M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, AngioLab, Inc.'s stock has declined approximately 34.47% over the past 52 weeks. The 50-day moving average sits at 2,745.56, while the 200-day moving average is 2,289.77.

Over the twelve months ended December 31, 2025, AngioLab, Inc. generated 2.26B in revenue and converted that into -554.43M in net income, yielding earnings per share of -173.73. EBITDA reached -501.23M, while operating income came in at -602.61M.

As of December 31, 2025, AngioLab, Inc. holds 1.35B in cash and equivalents against 21.36M in total debt, resulting in a net debt position of -196.44M. Total book value stands at 1.29B, with working capital of 1.13B providing operational flexibility.

AngioLab, Inc. produced -756.98M in operating cash flow over the twelve months ended December 31, 2025. After subtracting -120.29M in capital expenditures, free cash flow totaled -877.27M - equivalent to -274.89 per share.

Over the twelve months ended December 31, 2025, AngioLab, Inc. posted a gross margin of 62.29, reflecting its pricing power and cost economics. The operating margin of -26.61 and net profit margin of -24.48 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield is negative at -11.17: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -10.93, meaning AngioLab, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of December 31, 2025, AngioLab, Inc. has an Altman Z-Score of -12.76, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.